Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (June 2026)
13 slides from Qiagen's investor day presentation, Jun 15, 2026
Slide 1: Deep Dive: QIAcuity digital PCR
Deep Dive QIAcuity digital PCR ADDRESSING THE GROWING DIGITAL PCR OPPORTUNITY June 15, 2026
Slide 2: Forward Looking and Intended Use Statements
FORWARD LOOKING AND INTENDED USE STATEMENTS Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Expanding dPCR into the space between qPCR and NGS
dPCR opportunity Execution Adoption Differentiation Gene expression Assay menu EXPANDING DPCR INTO THE SPACE BETWEEN QPCR AND NGS Quantitative PCR Next-generation (qPCR) QIAcuity dPCR sequencing (NGS) Making high-precision PCR e.g., Gene expression more accessible e.g., Liquid biopsy Lower accuracy
Slide 4: Executing against our growth priorities
dPCR opportunity Execution Adoption Differentiation Gene expression Assay menu EXECUTING AGAINST OUR GROWTH PRIORITIES <2 hours run time Why we win More than 1,500 samples per day(1) Ease of use Leveraging qPCR-like usability $89 mn Up to 12 targets 2025 net sales Measured in a single reaction throu
Slide 5: QIAcuity: Scaling digital PCR adoption
dPCR opportunity Execution Adoption Differentiation Gene expression Assay menu QIACUITY: SCALING DIGITAL PCR ADOPTION Key achievements QIAcuity One QIAcuity Four QIAcuity Eight QIAcuityDx >3,200 cumulative placements Academia since 2020 launch Overcoming entry barrier vs. qPCR Translational and canc
Slide 6: Growth through clear differentiation
dPCR opportunity Execution Adoption Differentiation Gene expression Assay menu GROWTH THROUGH CLEAR DIFFERENTIATION Sales in mn $ Placements ~55% 100 3,000 75 Sales CAGR 2,000 (2020-25) 50 25 1,000 ~75% Installed base 0 0 CAGR (2020-25) 2020 2021 2022 2023 2024 2025 QIAGEN Competitor B Competitor T
Slide 7: Why customers choose QIAcuity
WHY CUSTOMERS CHOOSE QIACUITY What I value most about QIAcuity digital PCR is compared to other digital platforms where you have to use multiple equipment, the one unit does everything from partitioning the plates, doing the PCR and imaging. Prof. Prashant Singh, Florida State University, U.S. We ca
Slide 8: Case study from R&D into quality control
CASE STUDY FROM R&D INTO QUALITY CONTROL Cell and gene therapy Expanding dPCR adoption across CGT development and QC Biopharma customer adoption journey One scalable ecosystem across QIAcuity One, Four and Eight Initial adoption of QIAcuity dPCR for viral vector titer analysis in R&D Consistent user
Slide 9: Gene expression: growing opportunity for QIAcuity
dPCR opportunity Execution Adoption Differentiation Gene expression Assay menu GENE EXPRESSION: GROWING OPPORTUNITY FOR QIACUITY A large and growing market What is gene expression? Measuring which genes are turned on or off and by how ~$2.7 bn qPCR addressable market in 2025 Overcome qPCR limitation
Slide 10: Launching new gene expression solutions
dPCR opportunity Execution Adoption Differentiation Gene expression Assay menu LAUNCHING NEW GENE EXPRESSION SOLUTIONS QIAcuity assays - QIAcuity OneStep Gene expression Ready-to-use multiplex High Multiplex Mix New chemistry enabling >17,000 dPCR assays for analysis of up to gene expression human,
Slide 11: GeneGlobe: expanding the QIAcuity dPCR assay menu
dPCR opportunity Execution Adoption Differentiation Gene expression Assay menu GENEGLOBE: EXPANDING THE QIACUITY DPCR ASSAY MENU Gene expression Enabling high-multiplex analysis of gene activity Cancer research Custom assay design Identifying rare mutations Maximizing value through unlimited and bio
Slide 12: QIAcuity dPCR: Addressing the growing digital PCR opportunity
QIACUITY DPCR: ADDRESSING THE GROWING DIGITAL PCR OPPORTUNITY Ease of use Proven Leveraging qPCR-like usability to reduce adoption barriers for dPCR through growing QIAcuity placements Throughput flexibility Purpose-built Capturing all customer needs from low- to high-throughput testing for low- to
Slide 13: QIAcuity digital PCR
QIAcuity digital PCR ADDRESSING THE GROWING DIGITAL PCR OPPORTUNITY